Apixaban - CAS# 503612-47-3 size:2mg solid 4 nM) or resorption area

4 nM) or resorption area (IC50=6

Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma

PubMed Central PMCID: PMC3706837

Coinhibition of the deubiquitinating enzymes

CCR-17-3265

Apixaban - CAS# 503612-47-3 size:2mg solid 4 nM) or resorption areaApixaban, CAS No. 503612 47 3, also known as BMS 56224701, is an anticoagulant for the treatment of venous thromboembolic events. Apixaban is a direct factor Xa inhibitor. Apixaban was approved in 2012. Apixaban is indicated for the following: (1) To lower the risk of stroke and embolism in patients with nonvalvular atrial fibrillation. (2) Deep vein thrombosis (DVT) prophylaxis. DVT's may lead to pulmonary embolism (PE) in knee or hip replacement